The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Open accessAbstract
NAMI-A ((ImH)[trans-RuCl4(dmso-S)(Im)], Im = imidazole) and KP1019/1339 (KP1019 = (IndH)[trans-RuCl4(Ind)2], Ind = indazole; KP1339 = Na[trans-RuCl4(Ind)2]) are two structurally related ruthenium(III) coordination compounds that have attracted a lot of attention in the medicinal inorganic chemistry scientific community as promising anticancer drug candidates. This has led to a considerable amount of studies on their respective chemico-biological features and to the eventual admission of both to clinical trials. The encouraging pharmacological performances qualified KP1019 mainly as a cytotoxic agent for the treatment of platinum-resistant colorectal cancers, whereas the non-cytotoxic NAMI-A has gained the reputation of being a very effective antimetastatic drug. A critical and strictly comparative analysis of the studies conducted so far on NAMI-A and KP1019 allows us to define the state of the art of these experimental ruthenium drugs in terms of the respective pharmacological profiles and potential clinical applications, and to gain some insight into the inherent molecular mechanisms. Despite their evident structural relatedness, deeply distinct biological and pharmacological profiles do emerge. Overall, these two iconic ruthenium complexes form an exemplary and unique case in the field of medicinal inorganic chemistry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Noble metals in medicine: Latest advances
Medici, S., Peana, M., Nurchi, V. M., Lachowicz, J. I., Crisponi, G., & Zoroddu, M. A. (2014) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.08.002 · Cited by 755
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Trondl, R., Heffeter, P., Kowol, C. R., Jakupec, M. A., Berger, W., & Keppler, B. K. (2014) · Chem. Sci. · doi:10.1039/c3sc53243g · Cited by 675
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Recent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Bruno, P. M., Liu, Y., Park, G. Y., Murai, J., Koch, C. E., Eisen, T. J., Pritchard, J. R., Pommier, Y., Lippard, S. J., & Hemann, M. T. (2017) · Nature Medicine · doi:10.1038/nm.4291 · Cited by 519
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Self-citationRu(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
Meier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., & Keppler, B. K. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00332c · Cited by 425
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
Self-citationLeijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0179-1 · Cited by 374
Self-citationMetal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Ruthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
Metal-based antitumour drugs in the post-genomic era: what comes next?
Sava, G., Bergamo, A., & Dyson, P. J. (2011) · Dalton Transactions · doi:10.1039/c1dt10522a · Cited by 231
Ruthenium Anticancer Compounds: Challenges and Expectations
Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E. (2007) · CHIMIA · doi:10.2533/chimia.2007.692 · Cited by 225
Self-citationLinking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 219
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
Sava, G., Capozzi, I., Clerici, K., Gagliardi, G., Alessio, E., & Mestroni, G. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006521715400 · Cited by 183
Self-citationReisner, E., Arion, V. B., Guedes da Silva, M. F. C., Lichtenecker, R., Eichinger, A., Keppler, B. K., Kukushkin, V. Y., & Pombeiro, A. J. L. (2004) · Inorganic Chemistry · doi:10.1021/ic049479c · Cited by 173
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Heffeter, P., Böck, K., Atil, B., Reza Hoda, M. A., Körner, W., Bartel, C., Jungwirth, U., Keppler, B. K., Micksche, M., Berger, W., et al. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0642-1 · Cited by 173
Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
Coverdale, J. P. C., Laroiya-McCarron, T., & Romero-Canelón, I. (2019) · Inorganics · doi:10.3390/inorganics7030031 · Cited by 161
Bergamo, A., Gagliardi, R., Scarcia, V., Furlani, A., Alessio, E., Mestroni, G., & Sava, G. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38169-8 · Cited by 160
Self-citationBurris, H. A., Bakewell, S. J., Bendell, J. C., Infante, J. R., Jones, S. F., Spigel, D. R., Weiss, G. J., Ramanathan, R. K., Ogden, A., & Hoff, D. D. V. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000154 · Cited by 157
Serum Proteins as Drug Carriers of Anticancer Agents: A Review
Kratz, F., & Beyer, U. (1998) · Drug Delivery · doi:10.3109/10717549809065759 · Cited by 156
Dömötör, O., Hartinger, C. G., Bytzek, A. K., Kiss, T., Keppler, B. K., & Enyedy, É. A. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0944-6 · Cited by 145
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
Bergamo, A., Dyson, P. J., & Sava, G. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.009 · Cited by 139
Flocke, L. S., Trondl, R., Jakupec, M. A., & Keppler, B. K. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0337-8 · Cited by 135
Bijelic, A., Theiner, S., Keppler, B. K., & Rompel, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00600 · Cited by 128
Liu, M., Lim, Z. J., Gwee, Y. Y., Levina, A., & Lay, P. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200906079 · Cited by 122
Zorzet, S., Bergamo, A., Cocchietto, M., Sorc, A., Gava, B., Alessio, E., Iengo, E., & Sava, G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38990-6 · Cited by 120
Self-citationRuthenium-based compounds and tumour growth control (review).
Sava, G., & Bergamo, A. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.2.353 · Cited by 118
Bytzek, A. K., Koellensperger, G., Keppler, B. K., & Hartinger, C. G. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.02.037 · Cited by 114
Groessl, M., Tsybin, Y. O., Hartinger, C. G., Keppler, B. K., & Dyson, P. J. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0635-0 · Cited by 106
Gava, B., Zorzet, S., Spessotto, P., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095141 · Cited by 94
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
Morbidelli, L., Donnini, S., Filippi, S., Luigi Messori, A., Piccioli, F., Orioli, P., Sava, G., & Ziche, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600906 · Cited by 92
Sava, G., Frausin, F., Cocchietto, M., Vita, F., Podda, E., Spessotto, P., Furlani, A., Scarcia, V., & Zabucchi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.034 · Cited by 91
Pal, M., Nandi, U., & Mukherjee, D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.015 · Cited by 89
Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR
Cetinbas, N. M., Webb, M. I., Dubland, J. A., & Walsby, C. J. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0578-5 · Cited by 85
Heffeter, P., Pongratz, M., Steiner, E., Chiba, P., Jakupec, M. A., Elbling, L., Marian, B., Körner, W., Sevelda, F., Micksche, M., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073395 · Cited by 76
Vergara, A., D’Errico, G., Montesarchio, D., Mangiapia, G., Paduano, L., & Merlino, A. (2013) · Inorganic Chemistry · doi:10.1021/ic4004142 · Cited by 70
Ruthenium and Other Non‐Platinum Anticancer Compounds
Bratsos, I., Gianferrara, T., Alessio, E., Hartinger, C. G., Jakupec, M. A., & Keppler, B. K. (2011) · Wiley eBooks · doi:10.1002/9783527633104.ch5 · Cited by 54
Self-citationDepenbrock, H., Schmelcher, S., Peter, R., Keppler, B. K., Weirich, G., Block, T. R., Rastetter, J., & Hanauske, A.-R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00277-3 · Cited by 54
Cebrián-Losantos, B., Reisner, E., Kowol, C. R., Roller, A., Shova, S. G., Arion, V. B., & Keppler, B. K. (2008) · Inorganic Chemistry · doi:10.1021/ic800506g · Cited by 52
Ru III Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic
Riccardi, C., Musumeci, D., Irace, C., Paduano, L., & Montesarchio, D. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201600943 · Cited by 51
Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs
Schreiber‐Brynzak, E., Klapproth, E., Unger, C., Lichtscheidl, I., Göschl, S., Schweighofer, S., Trondl, R., Dolznig, H., Jakupec, M. A., & Keppler, B. K. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0260-4 · Cited by 48
EPR as a probe of the intracellular speciation of ruthenium(iii) anticancer compounds
Webb, M. I., & Walsby, C. J. (2013) · Metallomics · doi:10.1039/c3mt00090g · Cited by 48
Luck, A. N., & Mason, A. B. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.11.001 · Cited by 47
Comparison of KP1019 and NAMI-A in tumour-mimetic environments
Gransbury, G. K., Kappen, P., Glover, C. J., Hughes, J. N., Levina, A., Lay, P. A., Musgrave, I., & Harris, H. H. (2016) · Metallomics · doi:10.1039/c6mt00145a · Cited by 43
Brindell, M., Piotrowska, D., Shoukry, A. A., Stochel, G., & van Eldik, R. (2007) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-007-0234-x · Cited by 42
Webb, M. I., & Walsby, C. J. (2015) · Dalton Transactions · doi:10.1039/c5dt02021b · Cited by 41
Jassem, J., Krzakowski, M. J., Roszkowski, K., Ramlau, R., Słomiński, J. M., Szczęsna, A., Krawczyk, K., Możejko-Pastewka, B., Lis, J., & Miracki, K. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00286-0 · Cited by 37
The NAMI A – human ferritin system: a biophysical characterization
Ciambellotti, S., Pratesi, A., Severi, M., Ferraro, G., Alessio, E., Merlino, A., & Luigi Messori, A. (2018) · Dalton Transactions · doi:10.1039/c8dt00860d · Cited by 33
Self-citationBlazevic, A., Hummer, A. A., Heffeter, P., Berger, W., Filipits, M., Cibin, G., Keppler, B. K., & Rompel, A. (2017) · Scientific Reports · doi:10.1038/srep40966 · Cited by 32
Impact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin
Śpiewak, K., & Brindell, M. (2015) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-015-1255-5 · Cited by 27
Golla, U., Swagatika, S., Chauhan, S., & Tomar, R. S. (2017) · Oncotarget · doi:10.18632/oncotarget.21416 · Cited by 26
Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNAPhe
Dwyer, B. G., Johnson, E., Cazares, E., Holman, K. L. M., & Kirk, S. R. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.02.019 · Cited by 23
Hostetter, A. A., Miranda, M. L., DeRose, V. J., & Holman, K. L. M. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0806-7 · Cited by 22
Casarsa, C., Mischis, M. T., & Sava, G. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.017 · Cited by 21
Fuereder, T., & Berger, W. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000239 · Cited by 16
Metadata
- Authors
- Alessio, E., & Messori, L.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-05-24
- Volume
- 24
- Issue
- 10
- Pages
- 1995
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2945041466
- Cited by
- 385
- References
- 70
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.